Financial Times reporter Hannah Kuchler writes that researchers from MIT and a number of other institutions have called for a moratorium on editing inheritable human genes. Kuchler writes that the researchers called for the establishment of “an international framework on the conditions in which such editing could be allowed.”
MIT spin-off Gingko Bioworks was named to the CNBC Disruptor 50 List for using “genetic engineering to design and print new DNA for a variety of organisms…that can then be used for anything from killing antibiotic-resistant germs to producing artificial sweetener and cheaper perfume,” reports Tom Huddleston Jr. for CNBC.
In an article for STAT, Prof. Kevin Esvelt argues that non-profits should be the only entities allowed to develop and use new genome editing technologies. Esvelt writes that when it comes to controversial new technologies like gene drive, “keeping early applications in the nonprofit realm could help us make wiser decisions about whether, when, and how to move forward.”
CNN reporter Bronte Lord spotlights Prof. Kevin Esvelt’s proposal to introduce genetically engineered mice to the islands of Martha’s Vineyard and Nantucket in an effort to stop the spread of Lyme disease. "We want to heritably immunize the local white-footed mice," Esvelt explains. "The idea is fewer infected ticks means fewer infected kids."
Prof. Kevin Esvelt speaks with Dylan Matthews of Vox about the potential for a CRISPR gene drive to eradicate malaria. Esvelt considers both the risks and rewards of this approach, noting that “the future of our civilization will primarily be determined by the technologies we develop and the wisdom with which we choose to deploy them or refrain.”
During this episode of NOVA Wonders, Professors Kristala Jones Prather and Kevin Esvelt discuss the future of genetic engineering. Speaking about the evolution of the biotech industry, Prather explains that, "the key observation that really fueled the entire biotech industry was recognizing that D.N.A. is really just a chemical, and the structure is what matters.”
Co-founded by Prof. Feng Zheng, Beam Therapeutics, which uses CRISPR to treat disease, has secured $87 million in initial funding, reports Clive Cookson for Financial Times. Beam is the first company to use base editing, which changes the chemical “letters” of genetic code without cutting it, similar to “moving from scissors-and-paste to editing text with a sharp pencil,” explains Cookson.
WBUR's Carey Goldberg profiles Prof. Feng Zhang, a “sunny science superstar” whose discoveries include major advances in optogenetics and CRISPR. "Feng is a one-in-a-generation scientist who sees connections that the rest of us have overlooked," says Prof. Robert Desimone, director of the McGovern Institute for Brain Research at MIT.
Co-founded by three alumni and a former professor, startup Ginkgo Bioworks uses genetic engineering to create an array of consumer and corporate products – all relying on socially conscious GMOs. The company, which is now partnering with Bayer, is “trying to reset the conversation around biotechnology: by foregrounding the benefits to consumers and advocating for transparency,” writes Sarah Zhang for The Atlantic.
Prof. Kevin Esvelt speaks with Scientific American reporter Elie Dolgin about his work applying genetic engineering to eradicate diseases like malaria. Esvelt explains that one day researchers could potentially, “engineer an organism that would confer disease resistance to an entire species. Ideally, we’d want to start small and local, see how well it works, and only then scale up if it’s warranted.”
In an attempt to curb the increase in Lyme disease on Nantucket, Prof. Kevin Esvelt has proposed using gene-editing technology to engineer mice that can combat the spread of the disease, reports Cristina Quinn for WGBH. The idea is to, “genetically engineer these mice so that they are immune to the bacteria that causes Lyme disease.”
MIT researchers have genetically engineered E.coli bacteria to replicate light and create images in a range of different colors, reports Alexandra-Simon Lewis for Wired. In the future, the technique could be used to make “bacteria produce more complex molecules on-demand by using light to stop and start chemical reactions.”
Prof. Kevin Esvelt has been honored as a 2017 Boston Globe “Game Changer” for his work with genetic engineering. Ike Swetlitz notes that, “As biology advances at breakneck speed and international debate rages about the ethics and politics of releasing genetically engineered animals, Esvelt has emerged as a respected leader.”
Boston Herald reporter Jordan Graham writes that a committee co-chaired by Prof. Richard Hynes has made a series of recommendations for the use of gene editing in humans. Graham explains that the committee recommended “leaving the door open to altering the human genome in ways that would affect the descendants of patients with hereditary diseases and disabilities.”
A committee co-chaired by Prof. Richard Hynes has presented a set of guidelines for using the CRISPR gene-editing tool in humans, reports Lauran Neergaard for the AP. Neergaard writes that Hynes noted, “safety is one reason for caution, as scientists will have to learn whether editing one gene has unwanted downstream effects.”